Recent Advancements in Tuberculosis Drug Discovery

PART I: UNDERSTANDING TUBERCULOSIS (TB) AND ITS CHALLENGES

1. Tuberculosis Drug Discovery: From Evil to Allies

Nirjhar Saha, Mainak Chatterjee, Tejas M. Dhameliya, and Asit K. Chakraborti

2. Relationship Between Covid-19 and Tuberculosis

Kevin Flores-Lovon, Edwin Herrera, Paola Salinas, and Rodney Macedo

3. Advancement in the Diagnosis of Tuberculosis

Ruchi Nair, Pooja Thakur, and Hitesh D. Patel

4. Mechanisms of Drug Resistance in Tuberculosis and Potential Modulation Strategies

Nandini Gupta, Ramesh Goyal, and Bhoomika Patel

PART II: NEW FRONTIERS IN TB DRUG DISCOVERY

5. Outsmarting the Superbug: A Look at New Targets for Tuberculosis Treatment

Amit Chaudhari, Divya Teli, and Vivek P. Chavda

6. Deciphering Antitubercular Drug Pharmacokinetics

Shrinivas Savale and Rudri Khatri

7. Structure-Based Drug Design for Tuberculosis

Zankhana Nathavad, Lata Rani, Aleksandrs Gutcaits, and Pawan Gupta

PART III: SUCCESS STORIES AND EMERGING HOPE

8. The Journey of Bedaquiline: Revolutionizing Tuberculosis Treatment

M. R. Yadav, Dushyant Patel, Divya Teli, and Hiral Shah

9. Delamanid and Pretomanid: From Bench to Bedside

Meenakshi Jain, Himanshu Sharma, Menka, Tushar Dash, Rehan Hamdulay, and Rahul Jain

10. Overview of DprE1 Inhibitors and Development of Macozinone and Other Drugs

Saloni Yadav and Omprakash Tanwar

11. Unleashing the Power Within: Host Directed Therapies Revolutionizing Tuberculosis

Treatment

Md Sadique Hussain, Prince Ahad Mir, Nishant Kumar, Apporva Chawla, Roohi Mohi-Ud-Din, and Reyaz Hassan Mir

PART IV: TOOLS AND TECHNOLOGIES FOR A TB-FREE FUTURE

12. Artificial Intelligence in Tuberculosis Management

Vivek P. Chavda, Keshava L. Jetha, Nimeet Desai, Praful D. Bharadia, and Lalitkumar Vora

13. Novel Drug Delivery Systems for Tuberculosis Treatment

Hemali Savla, Bhushan Bhale, Nisha Sharma, and Pradnya Petkar

PART V: TOWARD A TB-FREE WORLD: VACCINES, BIOMARKERS, AND THE FUTURE

14. Advances in Tuberculosis Control: Vaccines and Biomarkers

Pankti Balar, Bedanta Bhattacharjee, Dixa Vaghela, Lalitkumar Vora, Vasso Apostolopoulos, and Vivek P. Chavda

15. Future Perspectives and Emerging Strategies in Tuberculosis Drug Discovery

Mahesh Chhabria and Divya Teli

Biography

Vivek P. Chavda, MPharm, is an Assistant Professor of Pharmaceutics and Pharmaceutical Technology at the L. M. College of Pharmacy, India. He earlier served in the biologics industry in research and development with two successful regulatory filings. He has more than 250 national and international publications, nearly 20 book chapters, several books, one patent in progress as well as numerous newsletter articles to his credit. His research interests include development of biologics processes and formulations, medical device development, nano-diagnostics, long-acting parenteral formulations, and nano-vaccines.

Mahesh T. Chhabria, PhD, is a Principal and Professor at the L. M. College of Pharmacy, India. He has around 70 research publications, one patent granted, and 10 patent applications to his credit. He has availed research grants of equating to nearly $1 million USD and has also received grants for setting up of the Atal Incubation Centre at the L. M. College of Pharmacy. He has supervised around nearly 150 MPharm and PhD students. His primary field of expertise revolves around medicinal chemistry and the utilization of computer-aided drug design methodologies, focusing on innovation and advancement of novel compounds targeting tuberculosis, hyperlipidemia, cancer, and COVID-19.

Divya M. Teli, MPharm, is an Assistant Professor of Pharmaceutical Chemistry at L. M. College of Pharmacy, India. She has industrial experience of five years in the Department of Research and Development at o2h discovery Pvt. Ltd. Her area of interest includes synthesis of small organic heterocyclic molecules and indigenous novel route development for the synthesis of active pharmaceutical ingredients, key starting materials and drug intermediates, route scouting, computer aided-drug design, discovery and development of novel antitubercular, and anticancer and antiviral agents.